Summary:
A 26 week, randomized, double-blind, parallel group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma-related events during treatment with Symbicort, a fixed combination of inhaled corticosteriod and a long-acting beta agaonist as compared to treatment with an inhaled corticosteriod alone in adult and adolescent (at least 12 years old) patients with asthma.
Qualified Participants Must:
• Be 12 years of age or older
•
Have had asthma forat least one year
•
Be treating your asthma daily
Qualified Participants May Receive:
All study testing and visits at no cost and compensation for your time and travel.